{"organizations": [], "uuid": "d001df73228f7d14eff2613046fc0e698f27d4f9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180405.html", "section_title": "Archive News &amp; Video for Thursday, 05 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-antares-pharma-says-fda-accepts-re/brief-antares-pharma-says-fda-accepts-resubmission-to-crl-for-xyosted-nda-idUSB8N1PJ007", "country": "US", "domain_rank": 408, "title": "BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.314, "site_type": "news", "published": "2018-04-05T20:28:00.000+03:00", "replies_count": 0, "uuid": "d001df73228f7d14eff2613046fc0e698f27d4f9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-antares-pharma-says-fda-accepts-re/brief-antares-pharma-says-fda-accepts-resubmission-to-crl-for-xyosted-nda-idUSB8N1PJ007", "ord_in_thread": 0, "title": "BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "antares pharma inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "crl", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 5 (Reuters) - Antares Pharma Inc:\n* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION\n* FDA CONSIDERED RESUBMISSION A COMPLETE, CLASS 2 RESPONSE & HAS ASSIGNED USER FEE GOAL DATE OF SEPT. 29, 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-05T20:28:00.000+03:00", "crawled": "2018-04-06T21:46:51.000+03:00", "highlightTitle": ""}